Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06228053
Title Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (SYNERGY-201)
Acronym SYNERGY-201
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Syntrix Biosystems, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.